PharmaTelevision - BioCity CEO, Glenn Crocker. A 'phoenix from the ashes' story resulting in the largest bioscience incubator in the UK.

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: BioCity CEO, Glenn Crocker. A 'phoenix from the ashes' story resulting in the largest bioscience incubator in the UK.

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Glenn Crocker, Chief Executive of BioCity.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

BioCity Nottingham: An incubation company helping life science start-up companies

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BIO 2011 in Washington DC. On this show I have Glenn Crocker, who is the CEO of BioCity based in Nottingham in the UK, welcome to the show.

Glenn Crocker:

Thank you.

Fintan Walton:

Glenn, as I said you are the CEO of a organization company called BioCity which is based in Nottingham, could you tell us what BioCity is about and how that company originated?

Glenn Crocker:

Okay, so fundamentally BioCity is about trying to make life science companies in the early stage of their development more successful, so we are an incubation company, we help start companies to create them from scratch sometimes and then provide all the facilities in the environment that helps them to grow and develop including the finance side of things as well.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Glenn Crocker

CEO

Glenn Crocker currently serves as CEO of BioCity Nottingham Ltd (BioCity). Glenn Crocker has a first degree in Genetics and a D Phil in Immunology from Oxford University. After a few years in post doctoral research, he joined Ernst & Young where he qualified as a chartered accountant. His work with E&Y focused on advising the biotechnology industry, spending several years in Palo Alto, California, and returning to Cambridge to head the UK biotechnology practice for the firm, focusing on business development and corporate finance transactions. In 2003 he joined BioCity Nottingham Ltd (BioCity) as Chief Executive and has grown the business substantially since then. In 2006 he jointly founded R5 Pharmaceuticals, a contract formulation and manufacturing business, and is a non-executive director of that company. Glenn is also a non-executive director of Medilink East Midlands and a board adviser to several other companies.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

BioCity Nottingham Ltd (BioCity)

BioCity Nottingham Ltd (BioCity) is one of Europe's largest bioscience incubators. Launched in 2003, the 129,000 sq ft award winning site currently hosts over 70 companies and 600 employees. The purpose of BioCity Nottingham is to provide a home for developing biotechnology and healthcare companies, with accommodation that is able to respond to a company's requirements by offering small highly flexible laboratory and office units, and grow-on space. It is able to cater for companies from 1 to about 80 employees. By using flexible lab and office leasing arrangements, a company's growth requirements can be easily accommodated and it is the ideal solution for many types of ventures, including: New start-ups University spin-outs Established SMEs Corporate relocations and expansions Overseas companies seeking to establish an EU base